| VVOS 0.1859 -17.34% | CLGN 0.4885 36.45% | AIM 0.2238 -13.39% | RDHL 1.0422 57.67% | PCG 13.505 -18.64% | TSLL 9.86 9.80% | COOT 0.593 28.91% | SOAR 0.245 12.96% | NVD 3.9699 -1.98% | FNGR 0.2344 -41.11% | NVDA 219.83 1.05% | BITO 10.595 1.39% | LGCL 0.0342 -12.08% | NCRA 2.95 56.08% | WBUY 1.03 24.10% | GPRO 0.7199 20.00% | INTC 89.52 0.06% | NU 14.5 1.40% | AEHL 6.99 97.46% | LGPS 1.27 19.81% | TSLA 365.71 4.86% | WETO 10.22 78.67% | AAL 13.425 -1.58% | YDDL 2.1606 30.95% | SPCX 143.21001 1.21% | IBIT 44.5078 1.38% | TQQQ 71.097 -1.05% | SOXS 49.88 0.12% | NOK 10.07 -1.37% | SQQQ 38.945 1.05% | PATH 18.655 2.78% | ABEV 2.88 0.70% | SPDN 8.545 0.65% | NCPL 0.7143 3.28% | SNAP 5.515 1.57% | SOXL 111.125 -0.19% | RZLV 2.89 -2.69% | IREN 36.145 1.96% | SOFI 17.855 -1.14% | SGOV 100.695 0.00% | XLU 42.26 -1.10% | RITR 0.0915 4.33% | BMNR 24.38 2.44% | BTG 5.48 -3.18% | F 13.975 0.68% | ETHA 18.595 1.22% | PURR 11.685 0.65% | NIO 4.335 -0.80% | ONDS 7.6899 -2.66% | AUR 5.52 -5.32%

Warren Davidson Sells Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

On March 23, 2026, Warren Davidson, a representative from Ohio's 8th district, sold shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC). The transaction was valued between $1,001 and $15,000. GE HealthCare is a prominent player in the healthcare technology sector, focusing on innovative solutions to improve patient care. The company competes with other major healthcare technology firms in delivering advanced medical imaging and diagnostics.

GE HealthCare is actively involved in the COMPASS consortium, a significant initiative aimed at enhancing precision cardio-oncology care in Europe. With a budget of €50.5 million, this five-year project involves over sixty partners and addresses cardiovascular risks in cancer patients. The initiative highlights the growing concern of heart-related complications, which are the second leading cause of death among cancer survivors, as noted by global studies.

At the ACC.26 conference, GE HealthCare plans to showcase its comprehensive cardiology portfolio, including AI-enabled imaging technologies and advanced software solutions. These innovations support clinicians in diagnosing, treating, and monitoring cardiovascular diseases. The American Heart Association reports that cardiovascular disease is the leading cause of death in the U.S., emphasizing the need for efficient detection and treatment solutions, which GE HealthCare aims to provide.

GE HealthCare is experiencing positive growth, supported by a $21.8 billion backlog and strong enterprise deal momentum. The Pharmaceutical Diagnostics segment has grown by 12.7%, driven by demand for contrast media and PET imaging. However, the company faces challenges such as tariff impacts, margin pressures, and uneven performance across segments and regions.

Despite these challenges, GEHC's shares have increased by 0.2% over the past six months, contrasting with the industry's 20.4% decline and the S&P 500 Composite's 0.5% decrease. This resilience is reflected in the current stock price of $73.04, with a market capitalization of approximately $33.29 billion. The company's focus on innovation and strategic growth positions it well for future success.

Published on: March 26, 2026